Schedule 13D ownership disclosure

DIANTHUS THERAPEUTICS INC COM

Common Stock, $0.001 par value · CUSIP: 252828108

Event date: 2025-09-11

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Fairmount Funds Management LLCReported CIK 0001802528

    Shares: 4,052,052.00 · Class: 9.9%

  • Fairmount Healthcare Fund II L.P.Reported CIK 0001769651

    Shares: 4,052,052.00 · Class: 9.9%

  • Fairmount SPV III, LLC

    Shares: 0.00 · Class: 0%

  • Peter Evan HarwinReported CIK 0001663607

    Shares: 4,052,052.00 · Class: 9.9%

  • Tomas KiselakReported CIK 0001830177

    Shares: 4,052,052.00 · Class: 9.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-090015
Form type
SCHEDULE 13D/A
Filer
Dianthus Therapeutics, Inc. /DE/
CIK
CIK 1690585
Filed
Sep 15, 2025
Reporting period
Sep 11, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub